Dysport (botulinum toxin type A; abobotulinumtoxinA)

Effective Date: 10/22/13
Date Developed: 9/3/13 by Albert Reeves MD
Last Approval Date: 1/26/16, 1/24/17, 1/23/18

Dysport is a commercial form of botulinum toxin (a neurotoxin which inhibits the release of acetyl choline from the presynaptic membrane of the neuromuscular junction, leading to paresis or paralysis).

Pre-Authorization Criteria:

Cervical dystonia: treatment in adults to decrease the severity of abnormal head position and neck pain in toxin-naive and previously treated patients.

Glabellar lines: temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adults younger than 65 years.

Off-Label: acquired nystagmus; anal fissures; hand dystonia; sialorrhea; spasticity of cerebral palsy (children/adolescents); tardive dyskinesia; migraine headaches refractory to other treatments

Adult Dosing: varies, see product information

PRECAUTIONS: should be administered by a practitioner specially trained in its use; distant spread of toxin beyond site of injection [U.S. Boxed Warning]; loss of efficacy due to antibody formation after prolonged use; unwanted reactions at injection sites (bleeding; excessive paresis); dry cornea/corneal abrasion from reduced blink reflexes

DRUG INTERACTIONS: neuromuscular blocking agents; anticholinergic agents; aminoglycosides

Note: Onabotulinum (Botox) and abobotulinumtoxin (Dysport) have unique dosing, as spelled out in each agent’s prescribing information. It is important that physicians be familiar with the respective dosing guidelines for each agent and be prepared to make appropriate treatment decisions in any clinical setting.
REFERENCES


23. Rowe FJ, Noonan CP. Botulinum toxin for the treatment of strabismus. Cochrane


Revision History:

Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 2/20/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>